Cannabis retail environment and treatment for cannabis use disorder.
This research investigates whether the efficacy of a digital cannabis use disorder (CUD) treatment for young adults (age 18-25) differs by exposure to cannab...
What This Lancet Review Really Says About Cannabinoids in Psychiatry
A new Lancet Psychiatry review examined 54 randomized trials of cannabinoids for mental disorders and substance use disorders, and the evidence was thinner than many public claims suggest. A few outcomes showed signals, especially in cannabis use…
Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know
WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class…
Cannabis Use Disorder Clinical Trial Pipeline Gains Momentum
The federal executive order on cannabis rescheduling does NOT make recreational marijuana legal—it eases research restrictions and tax burdens, but full legalization still requires an act of Congress. OpenPR reports that the clinical trial pipeline for…